The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 17, 2023
Cemiplimab (Libtayo) for NSCLC (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Cemiplimab (Libtayo) for NSCLC (online only)
April 17, 2023 (Issue: 1674)
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.